BDBM296521 US10112942, Example 255::US10137124, Example 255::US10172851, Example 255::US10555944, Example 255::US10953005, Example 255

SMILES CCOc1cc(-c2ccc(nc2)N2CCN(CC2)C(=O)C(N)c2ccc(F)cc2)c2c(cnn2c1)C#N

InChI Key InChIKey=DGTXPEXZCAZXKF-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 296521   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 14.4nMpH: 7.4Assay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 128nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 80.1nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 14.4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 128nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 80.1nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 14.4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 128nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 80.1nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 14.4nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 128nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 80.1nMAssay Description:The potency of a compound inhibiting G81 OR mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays containe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 14.4nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 128nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent

LigandPNGBDBM296521(US10112942, Example 255 | US10137124, Example 255 ...)
Affinity DataIC50: 80.1nMAssay Description:RET G810R: The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
Go to US Patent